BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Memento EPFL//
BEGIN:VEVENT
SUMMARY:ChemBio Seminar by Prof. Randall Peterson (University of Utah)
DTSTART:20231110T130000
DTEND:20231110T140000
DTSTAMP:20260528T235414Z
UID:889e368eff836814905fbd1059252680e2bd7647850d9aff716cfb1c
CATEGORIES:Conferences - Seminars
DESCRIPTION:Prof. Randall Peterson\, College of Pharmacy\, University of U
 tah\, USA\nTitle: Novel drugs\, novel genes from in vivo zebrafish screens
 \n\nAbstract:\nWhereas chemical biology and biochemistry have traditionall
 y focused on simple\, in vitro assays\, many biological phenomena—e.g. e
 mbryonic development\, disease physiology\, and behavior—are difficult t
 o reduce to in vitro assays. These organismal processes are best studied i
 n vivo\, and consequently have not historically been amenable to high-thro
 ughput biology. Now\, the zebrafish is allowing scientists to study these 
 organismal phenomena at unprecedented scale and throughput. We are develop
 ing methodologies that enable small molecule and CRISPR screening to be ap
 plied to organismal processes as diverse as social interaction and cardiac
  development. This talk will describe how small molecule screens in zebraf
 ish have led to new clinically useful compounds and share recent work usin
 g chemical and CRISPR screens to understand the causes of autism and conge
 nital cardiovascular malformations.\n\nSpeaker's biography:\n\n\n\n\nRanda
 ll Peterson is the L. S. Skaggs Presidential Endowed Professor and dean of
  the College of Pharmacy at the University of Utah. Peterson’s research 
 utilizes high-throughput screening technologies to discover new drug candi
 dates for cardiovascular and nervous system disorders. Peterson received a
  PhD in chemical biology from Harvard University\, where he studied as a H
 oward Hughes Medical Institute predoctoral fellow before completing a post
 doctoral fellowship at Massachusetts General Hospital. He was the Charles 
 Addison and Elizabeth Ann Sanders Chair in Basic Science at Harvard Medica
 l School\, Scientific Director of the MGH Cardiovascular Research Center\,
  and Senior Associate Member of the Broad Institute.  In the area of drug
  discovery\, he has used zebrafish screens to discover several compounds t
 hat are widely used research tools or in clinical trials.  In the area of
  genomics\, he has been at the forefront of developing genome editing tool
 s for the zebrafish\, including the first use of TALENs in zebrafish\, the
  first use of CRISPR in any animal\, the first engineering of Cas9 for alt
 ering PAM specificity\, and the first high-throughput CRISPR screen in a v
 ertebrate.  In the area of commercialization\, he is inventor on dozens o
 f patents and patent applications\, several of which have been licensed fo
 r commercial use.  He has served on the boards and scientific advisory bo
 ards of biotech and pharmaceutical companies and has founded several succe
 ssful companies\, including Keros Therapeutics (NASDAQ: KROS).  At the Un
 iversity of Utah\, he co-founded the University of Utah Therapeutics Accel
 erator Hub.\n\n\n\n\n\nLab website: https://pharmacy.utah.edu/pharmtox/ran
 dall/randall-peterson-lab\n\n\n 
LOCATION:SV 1717 https://plan.epfl.ch/?room==SV%201717
STATUS:CONFIRMED
END:VEVENT
END:VCALENDAR